Aptamer Sciences Inc (KOSDAQ:291650)
South Korea · Delayed Price · Currency is KRW 1,941.00
+1.00 (0.05%)
At close: Apr 3, 2026
Aptamer Sciences Revenue
In the year 2024, Aptamer Sciences had annual revenue of 1.08B KRW with 345.26% growth. Aptamer Sciences had revenue of 920.07M in the quarter ending December 31, 2024, with 5,471.58% growth.
Revenue
1.08B
Revenue Growth
+281.58%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
78.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.08B | 839.63M | 345.26% |
| Dec 31, 2023 | 243.19M | -115.07M | -32.12% |
| Dec 31, 2022 | 358.25M | 88.98M | 33.04% |
| Dec 31, 2021 | 269.28M | 40.77M | 17.84% |
| Dec 31, 2020 | 228.51M | -179.09M | -43.94% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 123.77B |
| Cell Biotech | 53.13B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Naturalendo Tech | 22.23B |
| Ark Solutions | 16.08B |
| PanGen Biotech | 13.42B |
| HLB Pep | 4.96B |
| EyeGene | 3.57B |